MGMT and glioblastoma: Two analyses have investigated the value of continuing temozolomide beyond adjuvant cycles after standard radiotherapy in glioblastoma.24,25 Both studies used a binary MGMT methylation status and reported no evidence of benefit from extended temozolomide in patients with methylated glioblastoma compared those with unmethylated glioblastoma (HR 0.89, 95%CI 0.63-1.2624 and HR 1.45, 95%CI 0.89-2.33).25 We observed similar benefit from standard temozolomide regimen across MGMT methylation groups (Table 3, Model 3).